CSI Market
Sign In | Register

Amag Pharmaceuticals inc (AMAG) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access AMAG Annual Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Amag Pharmaceuticals inc's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2020)
9 Months 		(Jun 30 2020) (Mar 31 2020) (Dec 31 2019) (Sep 30 2019)
Operating Activities
Income-31.47
Depreciation & amortization22.28
Amortization of Other Assets12.30
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.23
Inventories Decrease /-Increase1.24
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets7.32
Share-based Compensation8.10
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Investment Income Net Amortization Of Discount And Premium-
Fair Value Adjustment Of Settlement Rights-
Increase Decrease In Receivables From Collaboration-
Noncash Research and Developmentin Process Expense-
Noncash Research And Development In Process Expense-
Noncash Loss On Extinguishment Of Debt-
Increase Decrease In Prepaid Transaction Costs-
Marketable Securities Gain Loss-0.01
Impairment Of Intangible Assets Excluding Goodwill-
Increase Decrease In Contract With Customer Liability9.46
Noncash Lease Expense-
Non Cash Lease Expense1.42
Income taxes0.63
Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable26.33
Increase (Decrease) in Accounts Payable and Accrued Liabilities-58.26
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-5.80
Other Working Capital-0.63
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.09
Discontinued operations0.00
Net Cash flow from Operating Activities-6.76
Investing Activities
Capital Expenditures-0.48
Sale of Capital Items4.92
Proceeds from Sale and Maturity of Marketable Securities43.68
Payments to Acquire Marketable Securities-55.76
Real Estate Investments0.00
Business Combination Net Working Capital And Other Adjustments Cash Received-
Payments To Acquire Businesses Net Of Cash Acquired And Cash Received Net Working Capital And Other Adjustments-
Payments For Proceeds From Property Plant And Equipment-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-7.64
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.80
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-114.92
Payment Of Contingent Consideration-
Payments For Purchase Of Convertible Bond Hedge-
Proceeds From Issuance Of Term Loan-
Proceeds From Termination Of Bond Hedge And Warrants-
Payment To Former Shareholders-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents113.50
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.62
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-2.32
Total Cash Flow-15.03
4 historic quarters locked

Sign in to unlock the full Amag Pharmaceuticals inc cash flow history.

Sign In Create Free Account

About AMAG Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.